top of page
ProSeek Bio logo 2025.png

8 Million

Women will be lost to ovarian cancer by 2050 if we do nothing. (World Ovarian Cancer Coalition 2024)

Join ProSeek Bio to change the status quo

To empower women’s health decisions with new blood tests, starting with ovarian cancer (OC).

Our Vision

Screenshot_9-1-2025_114551_.jpeg

Our Solution

To empower women’s health decisions with new blood tests, starting with ovarian cancer (OC).

Screenshot_9-1-2025_114635_.jpeg
Screenshot_9-1-2025_114619_.jpeg

Our Solution

Clinicians involved in ovarian cancer diagnosis

  • Clinical input

  • Clinical study collaboration

​

Pathology laboratories with mass spectrometry

  • Scientific & regulatory input

  • Partnering for clinical implementation

 

Women’s health advocates

Input, education & outreach

Our founder designed the innovative LeMBA-MS glycoform biomarker platform technology, previously proven through licensing of esophageal cancer glycoform biomarkers.

A grant from the Ovarian Cancer Research Foundation enabled the discovery and initial validation of new early detection ovarian cancer biomarkers, with commercialization rights assigned to ProSeek Bio.

ProSeek Bio is developing multibiomarker in vitro diagnostic (IVD) kits for use on pathology labs’ clinical mass spectrometers:

OC-Asses Test

test to differentiate ovarian cancer from benign in women presenting with symptoms

OC-Screen Test

test to differentiate ovarian cancer from benign in women presenting with symptoms

Screenshot_9-1-2025_11478_.jpeg

Founder & CEO
Michelle Hill, PhD

Contact

©2024 by ProSeek Bio Pty Ltd (ABN 76 671 418 401).

bottom of page